作者
C Blomström-Lundqvist, V Traycov, PA Erba, H Burri, JC Nielsen, MG Bongiorni, J Poole, G Boriani, R Costa, J-C Deharo, LM Epstein, L Saghy, U Snygg-Martin, C Starck, C Tascini, N Strathmore
发表日期
2020
期刊
European Heart Journal
卷号
41
期号
21
页码范围
2012-2032
简介
Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy devices are potentially life-saving treatments for a number of cardiac conditions, but are not without risk. Most concerning is the risk of a cardiac implantable electronic device (CIED) infection, which is associated with significant morbidity, increased hospitalizations, reduced survival, and increased healthcare costs. Recommended preventive strategies such as administration of intravenous antibiotics before implantation are well recognized. Uncertainties have remained about the role of various preventive, diagnostic, and treatment measures such as skin antiseptics, pocket antibiotic solutions, anti-bacterial envelopes, prolonged antibiotics post-implantation, and others. Guidance on whether to use novel device alternatives expected to be less prone to infections and novel oral anticoagulants is also limited, as are definitions …
引用总数